Verastem Oncology (NASDAQ:VSTM) presented updated two-year median follow-up data today from its pivotal Phase 2 RAMP 201 trial at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting.
The results reinforce the long-term durability and safety of the AVMAPKI® FAKZYNJA® (avutometinib and defactinib) combination for patients with recurrent low-grade serous ovarian cancer (LGSOC).
The oral plenary presentation in San Juan, Puerto Rico, highlighted that patients remaining on the combination therapy for two years maintained the response levels and therapy duration observed in the primary analysis conducted over 13 months ago.
With a median follow-up of 24.9 months for ongoing patients, the efficacy measures—including median duration of response (mDOR) and median progression-free survival (mPFS)—remained consistent with earlier findings.
The data showed significant treatment persistence: 50% of patients with KRAS-mutated LGSOC and 30% of those with KRAS wild-type disease remained on the therapy for more than one year.
This longitudinal data suggests that the combination can be administered over extended periods to provide a durable clinical benefit in a disease known for its high recurrence rates and limited treatment options.
Meanwhile, the safety profile remained stable, with no new safety signals identified during the extended follow-up period.
The discontinuation rate due to adverse events was reported at 12%, a figure consistent with the primary analysis, suggesting that the tolerability of the RAF/MEK and FAK inhibitor duo supports long-term adherence.